Wave Life Sciences Ltd. (WVE) Financial Ratios
13 years of historical data (2013–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
1.86
↓-77% vs avg
5yr avg: 8.03
30Y Low2.2·High16.6
ROE
↑
-55.6%
↓+53% vs avg
5yr avg: -119.3%
30Y Low-267%·High-25%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
WVE Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Wave Life Sciences Ltd. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $1.1B | $2.9B | $1.7B | $536M | $552M | $163M | $309M | $272M | $1.2B | $931M | $596M |
| Enterprise Value | $533M | $2.3B | $1.4B | $368M | $501M | $42M | $154M | $157M | $1.1B | $792M | $446M |
| P/E Ratio → | -4.80 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 26.16 | 67.10 | 15.79 | 4.73 | 151.27 | 3.97 | 15.38 | 16.99 | 84.50 | 251.25 | 401.51 |
| P/B Ratio | 1.86 | 5.45 | 8.16 | 13.52 | — | 5.01 | 3.41 | 3.79 | 16.60 | 6.66 | 4.42 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
WVE EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 53.43 | 13.24 | 3.24 | 137.33 | 1.03 | 7.65 | 9.82 | 73.09 | 213.71 | 300.35 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
WVE Profitability
Margins and return-on-capital ratios measuring operating efficiency
Wave Life Sciences Ltd. earns an operating margin of -504.1%. Operating margins have compressed from -60.0% to -504.1% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -55.6% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 79.3% | 79.3% | 100.0% | 100.0% | 100.0% | 100.0% | -552.2% | -997.6% | -832.6% | -2041.2% | 73.5% |
| Operating Margin | -504.1% | -504.1% | -101.9% | -60.0% | -4459.3% | -310.1% | -763.9% | -1303.4% | -1106.7% | -2769.4% | -3725.7% |
| Net Profit Margin | -478.3% | -478.3% | -89.6% | -50.8% | -4434.7% | -298.4% | -746.7% | -1211.5% | -1017.4% | -2754.7% | -3730.7% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -55.6% | -55.6% | -77.9% | -145.1% | — | -198.5% | -184.8% | -267.2% | -137.6% | -74.3% | -38.4% |
| ROA | -41.3% | -41.3% | -30.9% | -27.3% | -91.6% | -50.3% | -53.2% | -66.7% | -61.4% | -58.9% | -33.6% |
| ROIC | — | — | — | — | — | — | — | — | — | -10056.9% | — |
| ROCE | -54.9% | -54.9% | -67.0% | -83.2% | -149.5% | -84.4% | -94.6% | -125.5% | -97.2% | -65.2% | -35.2% |
WVE Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $602M exceeds total debt of $18M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.12 | 0.81 | — | 0.92 | 0.32 | 0.45 | 0.14 | 0.02 | 0.00 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -1.11 | -1.32 | -4.25 | — | -3.71 | -1.71 | -1.60 | -2.24 | -0.99 | -1.11 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | -9586.06 | — | -7251.05 | -17065.17 | -165.34 |
Net cash position: cash ($602M) exceeds total debt ($18M)
WVE Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Wave Life Sciences Ltd.'s current ratio of 6.47x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 1.26x to 6.47x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.47 | 6.47 | 2.89 | 1.26 | 1.38 | 2.53 | 1.90 | 1.57 | 1.56 | 7.67 | 12.50 |
| Quick Ratio | 6.47 | 6.47 | 2.89 | 1.26 | 1.38 | 2.53 | 1.90 | 1.57 | 1.56 | 7.67 | 12.50 |
| Cash Ratio | 6.33 | 6.33 | 2.72 | 1.07 | 1.24 | 2.35 | 1.52 | 1.25 | 1.34 | 7.26 | 12.36 |
| Asset Turnover | — | 0.07 | 0.31 | 0.41 | 0.02 | 0.20 | 0.07 | 0.06 | 0.05 | 0.02 | 0.01 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 10.90 | 4.79 | 67.93 | — | — | 545.40 | 456.74 | 253.23 | 98.54 | — |
WVE Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Wave Life Sciences Ltd. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $169M | $138M | $106M | $79M | $52M | $39M | $34M | $29M | $27M | $23M |
Peer Comparison
Compare WVE with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 WVEYou | $1B | -4.8 | — | — | 79.3% | -504.1% | -55.6% | — | — |
 SRPT | $2B | -2.1 | — | — | 59.9% | -29.9% | -53.5% | -31.4% | — |
 IONS | $12B | -31.0 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 ARWR | $10B | -6099.2 | 86.9 | 66.8 | 100.0% | 11.9% | -0.5% | 9.3% | 3.0 |
 NTLA | $1B | -3.2 | — | — | 76.5% | -651.7% | -53.5% | -44.0% | — |
 BEAM | $3B | -36.3 | — | — | 84.0% | -274.6% | -8.1% | -31.1% | — |
 PRQR | $152M | -3.3 | — | — | 83.0% | -275.9% | -58.8% | — | — |
 ALNY | $39B | 124.2 | 68.6 | 83.0 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 REGN | $64B | 14.7 | 15.3 | 15.6 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 EDIT | $239M | -1.4 | — | — | 100.0% | -245.2% | -198.1% | — | — |
 CRSP | $5B | -7.8 | — | — | -6537.0% | -16191.4% | -30.2% | -22.3% | — |
| Healthcare Median | — | 23.1 | 14.4 | 19.0 | 64.0% | -4.2% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 13 years · Updated daily
What if you invested $1,000 in WVE 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in WVE be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs WVE Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationWVE vs SRPT — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Sarepta Therapeutics, Inc..
Compare NowWVE — Frequently Asked Questions
Quick answers to the most common questions about buying WVE stock.
What is Wave Life Sciences Ltd.'s P/E ratio?
Wave Life Sciences Ltd.'s current P/E ratio is -4.8x. This places it at the 50th percentile of its historical range.
What is Wave Life Sciences Ltd.'s ROE?
Wave Life Sciences Ltd.'s return on equity (ROE) is -55.6%. The historical average is -132.9%.
Is WVE stock overvalued?
Based on historical data, Wave Life Sciences Ltd. is trading at a P/E of -4.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Wave Life Sciences Ltd.'s profit margins?
Wave Life Sciences Ltd. has 79.3% gross margin and -504.1% operating margin.